Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain runs on a system where "wanting" something and "liking" something are two completely separate processes, managed by different circuits, and that distinction is the key to understanding what GLP-1 drugs are actually doing inside your head.

Most people assume those two things are the same. You want what you like, and you like what you want. But researchers who study reward circuitry have known for decades that the brain separates the drive to pursue a reward from the pleasure of receiving it, and GLP-1 receptor agonists appear to work specifically on the pursuit side without touching the pleasure side. That asymmetry is exactly why the effect is so invisible to the person experiencing it.

To understand why, you need the full chain first.

When your body processes food or anticipates a reward, a region in your gut and brain releases something called GLP-1, which stands for glucagon-like peptide-1, a hormone that normally signals fullness and regulates blood sugar. The drugs that carry this name, semaglutide, tirzepatide, retatrutide and others, are synthetic versions that activate the same receptors, but they do it much more powerfully and for much longer than the natural hormone does. The original therapeutic goal was to reduce appetite, and they accomplish that effectively. But GLP-1 receptors are not only in your gut. They sit inside the brain itself, including in the reward system, and activating them there has effects that have nothing to do with how hungry you feel.

The specific structure that matters here is something called the ventral tegmental area, or VTA, which is the engine of your brain's motivation system. The VTA is where dopamine neurons originate, and those neurons project outward into regions that generate the drive to seek, pursue, and initiate. When dopamine fires along this pathway, you feel pulled toward something. You think about it, you plan for it, you go get it. This is the wanting circuit.

Inside the VTA there are also something called GABA neurons, which function like a brake on the dopamine neurons. When GABA neurons fire, they suppress dopamine output. Research published in Science Advances in 2025 found that GLP-1 receptor activation in the VTA directly increases the firing of these GABA neurons, which in turn suppresses dopamine neuron activity and reduces reward-seeking behavior. The drug is not making dopamine disappear. It is pressing the brake harder than it normally would be pressed, and it is pressing it across every category of reward at once: food, yes, but also alcohol, novelty, sex, and anything else the dopamine system would normally push you toward.

Here is what makes this clinically strange. A 2025 study on semaglutide found that while the drug reduced what researchers call "wanting," meaning the motivation to pursue a reward, it did not reduce "liking," meaning the hedonic pleasure response when the reward was actually received. The dopamine system actually showed enhanced activity during what the researchers called the consummatory phase, the moment of actually experiencing the reward. So the experience itself is intact. The problem is upstream from the experience.

Think of it this way. The drug does not turn off the lights at the destination. It makes you far less likely to get in the car and drive there.

This is the mechanism behind the stories people tell about noticing a change only when they stop the drug. If something still feels good when it happens, your brain does not register it as broken. There is no pain signal, no obvious absence, no clear before-and-after while you are inside the effect. The drive to initiate is what disappears, and initiative is easy to attribute to stress, to being tired, to just not being in the mood, because all of those things also suppress initiative and this feels identical to them from the inside.

The dopamine pathway may not be working alone here either. A clinical review published in Obesity Pillars in 2025 proposed a second mechanism operating in parallel, involving something called 5-HT2C receptors, which are serotonin receptors that are already well known for suppressing sexual desire. SSRIs reduce libido in a significant portion of users through this receptor specifically, and the review proposed that GLP-1 agonists may upregulate activity at this same receptor, running the same brake through a completely separate biological pathway. The authors noted that this effect is often masked in clinical settings because the same patients are also losing weight, which tends to increase sexual function, so the two effects cancel each other out in the data and the suppressive effect goes undetected.

This does not mean the effect is rare or minor. It means the study designs used to evaluate these drugs were not set up to catch it.

The alcohol data points to how broad this reward suppression actually is. A randomized clinical trial published in JAMA Psychiatry in 2025 involving 48 adults with alcohol use disorder found that once-weekly semaglutide significantly reduced alcohol consumption, craving, and heavy drinking days. That is the same VTA GABA mechanism, the same dopamine brake, applied to a completely different reward category. The drug is not making choices about which rewards to suppress. It is suppressing the underlying motivational signal that all rewards share.

In terms of reversibility, these drugs have a half-life of approximately one week, which means that within four to five weeks of stopping, the pharmacological effect on receptor signaling has largely cleared and reward pathway activity returns to baseline. The effect is not permanent. It is not structural damage. It is an ongoing pharmacological state that resolves when the drug leaves the system.

One null result worth knowing: a four-week randomized placebo-controlled trial of dulaglutide in healthy men found no significant change in sexual function scores. But dulaglutide has weaker central nervous system penetration than semaglutide, and four weeks may not be long enough to observe the full effect, so that result does not overturn the mechanism so much as illustrate that not every drug in this class reaches the brain at the same intensity.

The practical implication is simple. If you are on one of these compounds and you have noticed less motivation across categories, less interest in things that used to pull at you, whether that is sex or hobbies or social plans or ambition, and you cannot find an obvious explanation for it, the pharmacology is a reasonable place to look first. The fact that you feel fine when those things are happening does not mean nothing changed. It means the part that changed is the part that makes you want to start.

That is the part most people are never told about.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness